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Objectives – To compare risk factors and survival in people with oropharyngeal 
cancer (OPC) and cancer unknown primary (CUP).  
 
Materials and methods – We recruited 5,511 people with head and neck cancer 
between 2011 and 2014. We collected data on age, gender, smoking, sexual 
behaviour, treatment intent, stage, co-morbidity, p16 protein overexpression and 
biological samples. We assessed human papillomavirus (HPV) status using 
serological response and p16 immunohistochemistry. We followed up participants to 
identify those who had died. We used Cox proportional hazards regression models 
to estimate survival and adjust for confounders. 
 
Results – Of the 4,843 people with squamous cell cancer 196 had CUP – a 
prevalence of 4.0% (95% CI 3.5% to 4.6%). Of those people with OPC and CUP 
69% (1150/1668) and 60% (106/178) respectively had HPV driven tumours. People 
with HPV driven tumours were likely to be younger, male, non-smokers, with higher 
stage disease, a history of oral sex and less co-morbidity. People with HPV negative 
CUP and HPV driven CUP had the survival of people with a stage II/III HPV negative 
OPC and a stage I/II  HPV driven OPC respectively. The adjusted hazard ratio for 
HPV driven OPC and CUP compared with HPV negative OPC and CUP was 0.46 
(95% CI 0.35 to 0.59) and 0.34 (95% CI 0.14 to 0.82) respectively.  
 
Conclusion – HPV driven CUP is likely to be HPV driven OPC. Identifying effective 
methods of detecting occult OPC could improve CUP management and allow the 
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In 2012 the estimated number of new cases of oropharyngeal cancer (OPC) worldwide 
was 100,500 with an age standardised incidence rate of 1.4 per 100,000 for both sexes 
combined.1 The incidence of OPC increased between 1983 and 2002 particularly in 
developed countries and at younger ages2 and more recent data from the United 
States3 and the United Kingdom suggests the incidence continues to increase.4 
Smoking and alcohol use are established major risk factors for OPC with a high 
attributable risk.5  
 
In the last twenty years human papillomavirus (HPV) has been recognised as an 
important cause of OPC. 6 A high and increasing proportion of OPC in North America 
and Europe are HPV driven. 7 These HPV driven tumours have a better prognosis 8 
and a strong serological response that reflects tumour HPV status. 9 
 
A small proportion (<5%) of cancers in the head and neck present as a neck lump with 
no primary tumour apparent at initial presentation and are referred to as carcinoma of 
unknown primary (CUP). 10-12 A substantial proportion of people with CUP have HPV 
driven tumours 13,14 with an associated strong serological response 15 and better 
prognosis. 13-17 Furthermore, intensive investigation shows that CUP is often occult 
OPC. 18,19 Some CUP arise in the nasopharynx and may be Epstein Barr virus (EBV) 
driven.  Recent guidance suggests that CUP should be divided into three categories 






No previous studies have prospectively recruited people with CUP and OPC from the 
same population and collected data to allow comparison of risk factors and survival 
based on HPV status. We report findings from head and neck 5000 a large clinical 




Patients and methods   
 
Study population 
Head and Neck 5000 is a large UK-based prospective clinical cohort study that has 
been described in detail previously. 21, 22 Briefly, 5,511 people with a new diagnosis 
of head and neck cancer were enrolled between April 2011 and December 2014. 
Data were collected using self-reported questionnaires and by abstracting 
information from the clinical notes at recruitment and 4 and 12 months later. A blood 
sample was collected at baseline and a formalin fixed tissue block along with a 
histopathology report were requested. Ethical approval for this study was given by 
the South West – Frenchay Regional Ethics Committee (ref: 10/H0107/57).  
 
Case definition 
We included two clinical groups - people with primary squamous cell carcinoma of 
the oropharynx (OPC) and people with metastatic squamous cell carcinoma to a 
neck node who were clinically assessed as having a cancer of unknown primary 
(CUP). Research staff at study centres completed a data abstraction form that 
recorded the clinical diagnosis. We used the following ICD codes to define the OPC 
(C01, C02.4, C05.1, C05.2, C05.8, C05.9, C09, C10) and CUP (C80.0) groups.  
Where the histopathology report was available, we cross checked the pathology 
report to confirm the histological diagnosis.  We did not provide centres with any 
criteria for defining or protocol for investigating cases of CUP. We abstracted the 
anatomical level of the pathological lymph node in the neck for CUP cases where 






Human papillomavirus status 
We assessed human papillomavirus (HPV) status using two sources of data. The 
first was the serological response to HPV antibodies from the blood sample taken at 
baseline. The second was the report of the measure of p16 status (as a surrogate 
marker) in tumour samples conducted by local clinical centres and abstracted from 
the pathology forms. While p16 alone is an imperfect measure of HPV driven 
tumours this is what was used in clinical practice at the time we enrolled people into 
Head and Neck 5000. We measured HPV antibodies using a glutathione S-
transferase multiplex assay carried out at the German Cancer Research Center 
(DKFZ) in Heidelberg, Germany. 23 We defined seropositivity as HPV16 E6 
antibodies with a cut-off value of > 1000 Median Fluorescence Intensity units (MFI). 
While this definition is sensitive and specific and widely used it may not capture all 
tumours driven by HPV16 and by HPV other serotypes. So we have included a 
sensitivity analysis using an extended approach that we have described previously 15 
to define seropositivity using additional criteria for HPV16 and for HPV18, HPV31, 
HPV33, HPV35, HPV45, HPV52 and HPV58. We have provided details of these 
criteria in Supplementary Table 1.  
 
Validation of the HPV status in people with CUP  
In a subset of participants with CUP where a formalin fixed paraffin embedded 
(FFPE) tissue sample had been supplied by the study centres we extracted DNA and 
RNA. 24 We prepared and reviewed hematoxylin and eosin stained slides before and 
after sectioning to ensure that tumour was present in sectioned tissue. We included 




using Multiplex Papillomavirus Genotyping. 25,26 Samples positive for HPV and/or 
beta-globin were considered to be DNA valid. We performed HPV RNA analysis, that 
is, detection of viral transcripts, by HPV type-specific reverse transcription 
polymerase chain reaction (RT-PCR) and hybridization assays, 24 which amplify HPV 
E6*I and ubiquitin C cDNA as a cellular mRNA quality control. We considered 
specimens that were HPV E6*I and/or ubiquitin C mRNA-positive to be RNA valid. 
Our gold standard for an HPV driven tumour was one that was both DNA and RNA 
positive. 
 
Measurement of Epstein Barr virus status in people with CUP 
We assessed Epstein Barr virus (EBV) status through qualitative identification of 
latent EBV infection using in-situ hybridisation (ISH) carried out on formalin fixed 
paraffin embedded tissue sections (3μm). We used a clinically validated automated 
BOND system. 27 When a tissue block was not available we abstracted information 
from the pathology reports provided by the diagnostic centre. 
 
Socio-demographic and lifestyle measures 
We used data from baseline health and lifestyle questionnaires to describe socio-
demographic and lifestyle measures of participants including age, gender, smoking 
and sexual behaviour. We calculated age using date of study consent and date of 
birth. We categorised smoking status as never, current or former smokers 
(previously smoked at least 100 cigarettes up until one year before diagnosis). We 
used responses to the question “how many different sexual partners have you 
performed oral sex on?” to group participants into three categories: never performed 






Research staff in local clinical centres abstracted information from medical notes. 
We derived the clinical staging of the tumour from T (characteristics of the tumour 
site), N (degree of lymph node involvement) and M (the absence or presence of 
metastases) based on the American Head and Neck Society TNM staging of head 
and neck cancer to compare stage between HPV seropositive and seronegative 
tumours. 28 We also used the staging proposed by the International Collaboration on 
Oropharyngeal Cancer Network for staging analyses of HPV seropositive tumours. 29 
We used the Adult Comorbidity Evaluation 27 (ACE 27) 30 form completed by 
research staff in clinical centres to record the presence and severity of medical 
comorbidities. We grouped participants into four categories: no co-morbidity, mild 
comorbidity; moderate decompensation and severe decompensation. We split 
participants into two groups based on treatment intent: those treated with curative 
intent, or those treated with palliative or supportive intent. We used treatment 
information collected at four months after recruitment. There were seven categories: 
1. surgery alone; 2. chemotherapy alone; 3. radiotherapy alone; 4. surgery and 




We flagged study participants with the UK Health and Social Care Information 
Centre and they provided regular notification of the date and cause of death of 
participants who had died. We measured survival time from study enrolment until 






We calculated the sensitivity, specificity and positive predictive value for HPV 
serology and clinical p16 measures in people with CUP.  We carried out analyses for 
OPC and CUP separately. We calculated 95% confidence intervals for proportions. 
We used chi-squared tests and student’s T tests to assess statistical evidence of 
difference between categorical variables and continuous variables respectively in 
HPV seropositive and seronegative groups. We plotted unadjusted Kaplan-Meier 
graphs to compare overall survival between HPV seronegative and HPV seropositive 
cancers with survival for OPC stratified by cancer stage. We used Cox proportional 
hazards regression models to estimate survival and to adjust for age, gender, stage 
(except CUP), treatment intent, co-morbidity and smoking. We repeated the 
unadjusted analyses for those with complete data for confounders used in the 
adjusted model. We performed a sensitivity analysis using an extended definition of 
seropositivity. We used the Head and Neck 5000 dataset version 2.5 in this study. All 








Number recruited to the study 
We have summarised the number of subjects in the study in Figure 1.  We had data 
on HPV status on 178 (91%) of the 196 CUP cases and on 1668 (88%) of the 1885 
OPC cases.   
 
Prevalence of CUP and clinical characteristics 
The prevalence of CUP SCC was 196/4,843 = 4.0% (95% CI 3.5% to 4.6%). In the 
103 people with CUP where we had data on the side and neck level 54 nodes were 
on the left and 49 were on the right. Ninety (87%) were located in level II, five in level 
I, six in level III and two in level IV suggesting that most were likely to have arisen 
from cancers in the head and neck. 
 
Validation of HPV status in people with CUP  
As the ability of serology and p16 to identify HPV driven OPC is established we 
defined an OPC as HPV driven if it was seropositive or if serum was not available if 
the clinical p16 was positive. The use of clinical p16 though imperfect allowed us to 
identify tumours that were likely to be HPV driven or not where serological data were 
not available to reduce the numbers with missing data and so increase the power of 
our analyses. To confirm the utility of this definition in CUP we compared the results 
of serology, tissue measures of HPV DNA and RNA and p16 immunohistochemistry 
in Figure 2. We had formalin fixed tissue available on 49 people with CUP. In 37 of 
these 49 people both DNA and RNA were positive. No-one with a tissue HPV 




were seronegative. The sensitivity, specificity and positive predictive value for 
serology based on HPV16 E6 >1000 were 91%, 100% and 100% respectively. Two 
of these three were considered seropositive when we used the extended definition of 
seropositivity. Both of these cases were HPV33 positive. All tissue HPV positive 
tumours were p16 positive but two tissue HPV negative tumours were p16 positive. 
The sensitivity, specificity and positive predictive value for clinical p16 were 100%, 
71% and 93% respectively. Based on these assay characteristics we used the same 
definition for HPV driven tumours in OPC and CUP. 
 
EBV status in people with CUP 
We had research EBER-ISH data available from formalin fixed tissue on 51 people 
with CUP and clinical EBER-ISH available from histopathological reports on 18 
people with CUP – a total of 64 people with CUP. Only one person with CUP was 
positive for EBER-ISH. The EBER-ISH positive case had a level 2 lymph node as 
was thought to have nasopharyngeal cancer but no primary lesion could be 
identified. 
 
Characteristics of people with OPC and CUP 
We present a comparison of baseline characteristics of people with OPC and CUP 
stratified by HPV status in Table 1. For people with OPC the prevalence of HPV 
positive tumours was 69% (1150/1668) and for people with CUP the prevalence of 
HPV positive tumours was 60% (106/178). People with HPV positive OPC were 
more likely than those with HPV negative OPC to be younger, male, higher stage, 
treated with curative intent, treated with chemoradiotherapy, to have a past history of 




People with HPV positive CUP showed similar differences compared to those with 





Survival comparisons between HPV positive and negative OPC and CUP 
We observed 448 deaths amongst the 1,668 people with OPC after a mean follow-
up time of 4.2 years and 48 deaths amongst the 178 people with CUP after a mean 
follow-up time of 4.1 years. We described survival for HPV positive and negative 
OPC and CUP in Figure 3. We then compared survival for HPV negative and 
positive OPC and CUP stratified by stage in Figures 4 and 5 respectively.  As only 
three participants with the HPV positive OPC were ICONS stage IV this group was 
combined with stage III for the analysis. Figure 3 shows that survival for HPV 
negative OPC and CUP is similar and that survival for HPV positive OPC and CUP is 
also similar. Figure 4 shows that HPV negative CUP has a similar survival to a stage 
II or III HPV negative OPC.  Figure 5 shows that HPV positive CUP has a similar 
survival to a stage I or II HPV positive OPC. We present the difference in survival for 
OPC and CUP by HPV status in Table 2. The survival benefit associated with being 
HPV positive is similar in both groups in unadjusted analyses. There is modest 
attenuation on adjustment for a range of potential confounding variables and 




We repeated the analyses using our extended HPV serology definition – the 
prevalence of HPV positivity was increased by 3% in both OPC and CUP. For people 
with OPC the prevalence of HPV positive tumours was 72% (1208/1668) and for 
people with CUP the prevalence of HPV positive tumours was 63% (112/178). The 







In this large prospective clinical cohort study the prevalence of CUP among all 
squamous cell cancers of the head and neck reported by study centres at baseline 
was around 4%. Of these, 60% of CUP were HPV driven. Based on similarities in 
risk factor profile and survival our data suggest that people with HPV driven CUP 
have HPV driven OPC. While people with HPV negative CUP are likely to have HPV 
negative OPC they could also have a primary elsewhere in the head and neck.  
 
The prevalence of CUP in our study was similar to that reported in other studies 10-12 
as was the prevalence of CUP that were HPV driven. 14 Our observation that 
serology can identify HPV driven CUP confirms a previous report 15 and is 
unsurprising as they are likely to represent HPV driven OPC. Our observation that 
people with HPV driven CUP have improved survival is consistent with that reported 
in a recent meta-analysis. 14 Our study was the first prospective study to recruit CUP 
and OPC cases contemporaneously. One previous retrospective study matched 
people with CUP to people with early stage OPC and reported similar survival 
between the two groups.32  
 
Our results support guidance that HPV status should be checked in people with 
CUP. 33 HPV positive CUP should be treated as HPV driven OPC after investigations 
have excluded other sites in the head and neck and sought to identify the site of the 
primary lesion in the oropharynx. 33 Further our findings support the conclusion by 
Ross et al 32 that HPV driven CUP could potentially be included in trials of HPV 




People with CUP may offer an ideal group to develop and test more effective 
techniques to identify occult OPC (as investigation is justified because it may alter 
treatment). Identification of early stage disease is a necessary first step in the 
development of screening programmes based on seroconversion. 
 
Our study had several strengths. First, this was a large prospective population- 
based observational study that reflects practice. Second, we recruited people with 
CUP and OPC contemporaneously. Third, we collected detailed data on health and 
lifestyle, HPV status and outcome. Our study also had a number of weaknesses. 
First, although the study was large the number of people with CUP enrolled was 
modest. Second, the diagnosis and investigation of CUP was not standardised. 
Third, those who participated and who completed questionnaires may not have been 
representative of all those eligible. Finally, clinical data on HPV status, EBV status 
and extra nodal extension required for staging were not recorded on many 
histopathology forms and p16 alone was used to identify HPV driven tumours in 
clinical practice. We were able to assess HPV status using serology for most people. 
Furthermore, based on those tested we conclude that few people with CUP had EBV 
driven cancers. Data were collected before staging of CUP was recommended so we 








We showed that HPV driven CUP is likely to be HPV driven OPC and that HPV 
negative CUP may well be HPV negative OPC. Efforts to find early OPC lesions (and 
early lesions at other sites) are justified to optimise care and improve prognosis. 
Further research to develop and test more effective methods of detecting occult OPC 
could improve management of people with CUP and allow the detection of early 
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Figure 1 Summary of people with oropharyngeal cancer and cancer of 
unknown primary with serology or clinical P16 data  
 
Figure 2 - Heat map displaying agreement between HPV DNA alone, HPV RNA 
alone, HPV serology using HPV16 E6>1000, an extended definition of HPV 
serology and p16 
 
Figure 3 - Kaplan Meier plots for OPC and CUP stratified by HPV status  
 
Figure 4 - Kaplan Meier plots for HPV negative OPC stratified by stage and HPV 
negative CUP 
 
Figure 5 - Kaplan Meier plots for HPV positive OPC stratified by ICONS stage and 








Table 1 - Risk factor profiles for HPV driven and HPV negative SCC of the oropharynx 
and cancer of unknown primary 
 Oropharynx Primary of unknown origin 
 Negative Positive p Negative Positive p 
N 518 1,150 - 72 106 - 
Age, mean (SD) 61.0 (9.5) 58.0 (8.7) <0.001 63.4 (10.8) 55.6 (8.4) <0.001 
Age group   <0.001    
   Less than 45 19 (3.7%) 60 (5.2%)  2 (2.8%) 8 (7.5%)  
   45 to 54 105 (20.3%) 334 (29.0%)  14 (19.4%) 41 (38.7%)  
   55 to 64 205 (39.6%) 496 (43.1%)  22 (30.6%) 39 (36.8%)  
   65 to 74 153 (29.5%) 210 (18.3%)  20 (27.8%) 17 (16.0%)  
   75 and over 36 (6.9%) 50 (4.3%)  14 (19.4%) 1 (0.9%)  
Sex   0.022   0.150 
   Male 388 (74.9%) 919 (79.9%)  55 (76.4%) 90 (84.9%)  
   Female 130 (25.1%) 231 (20.1%)  17 (23.6%) 16 (15.1%)  
TNM staging   <0.001   - 
   I 48 (9.3%) 20 (1.7%)  - -  
   II 82 (15.9%) 86 (7.5%)  - -  
   III 78 (15.1%) 153 (13.4%)  - -  
   IV 308 (59.7%) 886 (77.4%)  - -  
ICON-S staging   -   - 
   I - 653 (58.5%)   - -  
   II - 235 (21.1%)   - -  
   III - 225 (19.7%)  - -  
   IV - 3 (0.3%)  - -  
Treatment intent   <0.001   0.042 
   Curative 493 (95.2%) 1,146 (99.7%)  66 (91.7%) 104 (98.1%)  
   Palliative/supportive 25 (4.8%) 4 (0.3%)  6 (8.3%) 2 (1.9%)  
Treatment group   <0.001   0.190 
   Surgery only 47 (9.1%) 30 (2.6%)  7 (9.7%) 5 (4.7%)  
   Chemoradiotherapy only 253 (48.8%) 659 (57.3%)  25 (34.7%) 50 (47.2%)  
   Radiotherapy only 107 (20.7%) 106 (9.2%)  13 (18.1%) 12 (11.3%)  
   Surgery and radiotherapy 48 (9.3%) 127 (11.0%)  14 (19.4%) 12 (11.3%)  
   Surgery and chemoradiotherapy 51 (9.8%) 225 (19.6%)  11 (15.3%) 23 (21.7%)  
   Chemotherapy +/- surgery 9 (1.7%) 1 (0.1%)  1 (1.4%) 4 (3.7%)  
   No treatment 3 (0.6%) 2 (0.2%)  1 (1.4%) 0 (0.0%)  
Comorbidity index   <0.001   0.021 
   No comorbidity 172 (33.8%) 599 (53.1%)  31 (43.7%) 65 (64.4%)  
   Mild 194 (38.1%) 377 (33.4%)  20 (28.2%) 24 (23.8%)  
   Moderate  115 (22.6%) 133 (11.8%)  15 (21.1%) 10 (9.9%)  
   Severe 28 (5.5%) 20 (1.8%)  5 (7.0%) 2 (2.0%)  
Performed oral sex   <0.001   <0.001 
   Never performed 42 (14.9%) 34 (5.0%)  11 (26.8%) 4 (5.6%)  
   1-5 people 176 (62.4%) 382 (55.8%)  23 (56.1%) 35 (48.6%)  
   6+ people 64 (22.7%) 269 (39.3%)  7 (17.1%) 33 (45.8%)  
Tobacco   <0.001   0.110 
   Current user 142 (40.6%) 66 (7.7%)  10 (22.2%) 9 (10.1%)  
   Former 166 (47.4%) 496 (58.2%)  25 (55.6%) 50 (56.2%)  






Table 2 - Survival by HPV status in people with oropharyngeal cancer (OPC) and 
cancer of unknown primary (CUP) 
 Oropharynx 
(OPC) 
 Cancer of unknown primary 
(CUP) 
 HR p-value HR p-value 
 
All cases – unadjusted 
    
HPV status n = 1,668 <0.001 n = 178 <0.001 
   Negative 1.00 (Ref.)  1.00 (Ref.)  
   Positive 0.33 (0.27, 0.39)  0.33 (0.19, 0.60)  
 
Complete cases – 
unadjusted a 
    
HPV status n = 1,174 <0.001 n = 128 0.001 
   Negative 1.00 (Ref.)  1.00 (Ref.)  
   Positive 0.35 (0.28, 0.44)  0.29 (0.14, 0.62)  
 
Complete cases –  
adjusted b  
    
HPV status n = 1,174 <0.001 n = 128 0.017 
   Negative 1.00 (Ref.)  1.00 (Ref.)  
   Positive 0.46 (0.35, 0.59)  0.34 (0.14, 0.82)  
a OPC complete cases defined as having complete data for age, sex, stage, treatment modality, co-morbidity and 
smoking. *CUP complete cases defined as having complete data for age, sex, treatment modality, co-morbidity 
and smoking. 
b OPC models adjusted by age, sex, stage, treatment modality, co-morbidity and smoking. CUP models adjusted 














* HPV serology positive is based on HPV16 E6 >1000 MFI and the extended category 
includes cases that are negative using HPV16 E6 >1000 but positive using the extended 
HPV definition. The two additional positive cases were positive to HPV 33. 
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Supplementary Table S1 – Criteria for defining HPV seropositivity used in the 
sensitivity analysis (online only) 
 
Serotype Criteria * 
  
HPV16 E6 > 1000  
HPV16 3 of 4 (E1 >200, E2 >679, E6 >484 & <1000, E7 >548) 
  
HPV 18 3 of 4 (E1 >200, E2 >600, E6 >243, E7 >789) 
HPV 18 E6>243 and E7>789    
  
HPV31  E6 >890 and E7 >500 
  
HPV33  E6 >253 and E7 >500 
  
HPV35  E6 >271 and E7 >384 
  
HPV45  E6 >249 and E7 >200 
  
HPV52  E6 >271 and E7 >200 
  
HPV58  E6 >250 and E7 >200 






Supplementary Table S2 - Risk factor profiles for HPV driven SCC of the oropharynx 
and cancer unknown primary using HPV all and P16 
 Oropharynx Primary of unknown origin 
 Negative Positive p Negative Positive p 
N 460 1,208 - 66 112  
Age, mean (SD) 61.1 (9.6) 58.2 (8.7) <0.001 64.7 (10.1) 55.3 (8.4) <0.001 
Age group   <0.001    
   Less than 45 17 (3.7%) 62 (5.1%)  0 (0.0%) 10 (8.9%)  
   45 to 54 91 (19.8%) 348 (28.8%)  12 (18.2%) 43 (38.4%)  
   55 to 64 182 (39.6%) 519 (43.0%)  20 (30.3%) 41 (36.6%)  
   65 to 74 136 (29.6%) 227 (18.8%)  30 (30.3%) 17 (15.2%)  
   75 and over 34 (7.4%) 52 (4.3%)  14 (21.2%) 1 (0.9%)  
Sex   0.014   0.480 
   Male 342 (74.3%) 965 (79.9%)  52 (78.8%) 93 (83.0%)  
   Female 118 (25.7%) 243 (20.1%)  14 (21.2%) 19 (17.0%)  
TNM staging   <0.001   - 
   I 48 (10.5%) 20 (1.7%)  - -  
   II 79 (17.2%) 89 (7.4%)  - -  
   III 69 (15.1%) 162 (13.5%)  - -  
   IV 262 (57.2%) 932 (77.5%)  - -  
ICON-S staging   -   - 
   I - 653 (58.5%)  - -  
   II - 235 (21.1%)   - -  
   III - 225 (19.7%)  - -  
   IV - 3 (0.3%)  - -  
Treatment intent   <0.001   0.023 
   Curative 437 (95.0%) 1,102 (99.5%)  60 (90.9%) 110 (98.2%)  
   Palliative/supportive 23 (5.0%) 6 (0.5%)  6 (9.1%) 2 (1.8%)  
Treatment group   <0.001   0.140 
   Surgery only 47 (10.2%) 30 (2.5%)  7 (10.6%) 5 (4.5%)  
   Chemoradiotherapy only 216 (47.0%) 696 (57.6%)  23 (34.8%) 52 (46.4%)  
   Radiotherapy only 101 (22.0%) 112 (9.3%)  12 (18.2%) 13 (11.6%)  
   Surgery and radiotherapy 43 (9.3%) 132 (10.9%)  13 (19.7%) 13 (11.6%)  
   Surgery and chemoradiotherapy 41 (8.9%) 235 (19.5%)  9 (13.6%) 25 (22.3%)  
   Chemotherapy +/- surgery 9 (2.0%) 1 (0.1%)  1 (1.5%) 4 (3.6%)  
   No treatment 3 (0.7%) 2 (0.2%)  1 (1.5%) 0 (0.0%)  
Comorbidity index   <0.001   0.003 
   No comorbidity 150 (33.2%) 621 (52.4%)  26 (40.0%) 70 (65.4%)  
   Mild 165 (36.5%) 406 (34.2%)  19 (29.2%) 25 (23.4%)  
   Moderate  112 (24.8%) 136 (11.5%)  15 (23.1%) 10 (9.3%)  
   Severe 25 (5.5%) 23 (1.9%)  5 (7.7%) 2 (1.9%)  
Performed oral sex   <0.001   <0.001 
   Never performed 39 (15.8%) 37 (5.1%)  11 (30.6%) 4 (5.2%)  
   1-5 people 158 (64.0%) 400 (55.6%)  19 (52.8%) 39 (50.6%)  
   6+ people 50 (20.2%) 283 (39.3%)  6 (16.7%) 34 (44.2%)  
Tobacco   <0.001   0.037 
   Current user 138 (44.7%) 70 (7.8%)  10 (25.0%) 9 (9.6%)  
   Former 144 (46.6%) 518 (58.0%)  22 (55.0%) 53 (56.4%)  






Supplementary Table S3 - Survival by HPV status using HPV all and P16 
 Oropharynx  Primary of unknown 
origin 
 HR p-value HR p-value 
All cases – unadjusted  <0.001  <0.001 
HPV status n = 1,668  n = 178  
   Negative 1.00 (Ref.)  1.00 (Ref.)  
   Positive 0.28 (0.24, 
0.34) 
 0.30 (0.17, 
0.54) 
 
Complete cases – 
unadjusted a 
 <0.001  <0.001 
HPV status n = 1,174  n = 128  
   Negative 1.00 (Ref.)  1.00 (Ref.)  
   Positive 0.30 (0.24, 
0.38) 
 0.23 (0.11, 
0.49) 
 
Complete cases –  
adjusted b 
 <0.001  <0.001 
HPV status n = 1,174  n = 128  
   Negative 1.00 (Ref.)  1.00 (Ref.)  
   Positive 0.36 (0.27, 
0.47) 
 0.28 (0.11, 
0.70) 
 
a OPC complete cases defined as having complete data for age, sex, stage, treatment modality, co-morbidity and smoking.  
a PUO complete cases defined as having complete data for age, sex, treatment modality, co-morbidity and smoking. 
b OPC models adjusted by age, sex, stage, treatment modality, co-morbidity and smoking. PUO models adjusted by age, 
sex, treatment modality, co-morbidity and smoking. 
 
